secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zynerba Pharmaceuticals, Inc. (—)
CIK:        0001621443
Form:       8-K
Filed at:   2023-10-11T23:59:59+00:00
Accession:  0001140361-23-047687
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 2.01, 5.03, 3.01, 3.03, 5.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zynerba acquired by Harmony for $1.1059/share cash plus CVR worth up to $2.5444
-------------------------------------------------------------------------------

- Each Zynerba share converted into $1.1059 cash plus one CVR with max potential payments of $2.5444 per share.
- CVR milestones include $15M for RECONNECT trial completion by June 2026; up to $30M for meeting primary endpoint with statistical significance.
- Additional CVR milestones: $35M for first NDA approval, $15M for second; $15M for $250M cumulative net sales, $30M for $500M.
- Change in control: Zynerba became wholly owned by Harmony; board and officers replaced by Harmony designees.
- Shares to be delisted from Nasdaq; company intends to deregister under Section 12(g) of Exchange Act.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621443/000114036123047687/0001140361-23-047687-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621443/000114036123047687/ny20011256x2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-047687

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer